<DOC>
	<DOCNO>NCT02360709</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy deliverability CRE8 sirolimus-eluting stent system treatment patient de novo coronary artery lesion .</brief_summary>
	<brief_title>Safety Efficacy CRE8 Sirolimus-Eluting Stent Treatment De Novo Coronary Artery Lesions</brief_title>
	<detailed_description>This prospective , multi-center , single-arm observational registry trial plan enroll 800 subject . All 800 subject enrol receive CRE8 stent . Clinical follow-up perform 1 month , 6 months,12 month annually 5 year procedure .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Age ≥18 year ≤ 75 year , male female without pregnancy ; Patients clinical evidence asymptomatic heart disease , stable unstable angina , old myocardial infarction ; De novo lesion native coronary artery ; Target vessel diameter 2.25mm 4.5 mm , target lesion length ≤ 60mm visual estimation ; Target lesion diameter stenosis ≥ 70 % visual estimation ; Each target lesion must implant stent ( CRE8 ) ; Patients eligible percutaneous coronary intervention ( PCI ) acceptable candidate surgical revascularization ( CABG ) ; Patients leave ventricular ejection fraction ≥40 % ; Patients understand nature study , agree participate accept angiographic clinical followup , provide write informed consent . Patients acute myocardial infarction ( AMI ) within 72 hour ; Chronic total occlusion lesion ( TIMI flow 0 procedure ) , Left main disease and/or triplevessel lesion might require treatment ; Heavily calcify tortuous lesion successfully predilated , lesion suitable stent delivery deployment ; Instent restenosis ; Thrombotic lesion ; Patients receive stent past one year ; Patients acute chronic renal dysfunction ( define creatinine great 2.0 mg/dl ) ; Patients cardiogenic shock , acute infection , know bleed coagulation disorder , history active gastrointestinal bleeding , ulcer , cerebral hemorrhage subarachnoid hemorrhage stroke within 6 month ; Patients allergic aspirin , clopidogrel , ticagrelor , ticlopidine , heparin , contrast agent , sirolimus , polymer , CoCr alloy , contraindication aspirin clopidogrel ticagrelor ; Patients life expectancy le 1year ; Patients participate another investigational drug device trial complete primary endpoint ; Patient opinion investigator , unable comply requirement study protocol ; Patients underwent heart transplant surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>